These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3133817)

  • 21. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
    Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
    J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
    Francis RB; McGehee WG; Feinstein DI
    Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
    Xiong X; Zhao S; Wang Z; Lo L; Huang Q
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
    Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of venous occlusion on the PAI and antiplasmins release from platelets.
    Woods AI; Nadra CA; Lazzari MA
    Thromb Res; 1989 Nov; 56(3):491-5. PubMed ID: 2515615
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pathogenesis of skin pathologic changes and ulceration].
    Qian HS
    Zhonghua Yi Xue Za Zhi; 1993 Jun; 73(6):352-4, 381-2. PubMed ID: 8258106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke.
    Andreotti F; Davies GJ; Hackett DR; Khan MI; De Bart AC; Aber VR; Maseri A; Kluft C
    Am J Cardiol; 1988 Sep; 62(9):635-7. PubMed ID: 3137799
    [No Abstract]   [Full Text] [Related]  

  • 28. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
    Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
    Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fibrinolytic activity and tissue plasminogen activator level in healthy individuals prior to and after a ten-minute venous stasis].
    Kubicka A; Libura M; Sacha T; Swadźba J; Undas A; Wandzilak M
    Pol Tyg Lek; 1993 Feb 1-8; 48(5-6):116-9. PubMed ID: 8361905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Venous thrombosis following severe multiple trauma].
    Nast-Kolb D; Waydhas C; Kerim-Sade C; Jochum M; Spannagl M
    Orthopade; 1993 Apr; 22(2):110-6. PubMed ID: 8497393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered endothelial function following the Fontan procedure.
    Binotto MA; Maeda NY; Lopes AA
    Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective double-arm study of fibrinolysis in surgical patients.
    Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
    J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normal response to the tissue-type plasminogen activator after venous occlusion in a Fitzgerald trait patient.
    Vicente García V; D'Angelo A; Seveso P; Alberca I
    Thromb Haemost; 1985 Aug; 54(2):548. PubMed ID: 3936219
    [No Abstract]   [Full Text] [Related]  

  • 34. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
    Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
    J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
    Brommer EJ; Verheijen JH; Chang GT; Rijken DC
    Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preliminary results of the usefulness of fibrinolysis in vascular lesions of the legs].
    Faber W; Schneider M; Brommer E; Kraayenhagen R; Freen M; Hart H
    Phlebologie; 1990; 43(1):28-30. PubMed ID: 2112761
    [No Abstract]   [Full Text] [Related]  

  • 37. Release of von Willebrand factor after venous occlusion--the importance of standardization of venous occlusion tests.
    Scharrer I; Vigh Z
    Thromb Haemost; 1993 Nov; 70(5):880-1. PubMed ID: 8128453
    [No Abstract]   [Full Text] [Related]  

  • 38. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
    Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of plasminogen activator present in the endothelium of venous vessels on the development of thrombotic diseases].
    Czestochowska E
    Pol Tyg Lek; 1974 Apr; 29(14):587-9. PubMed ID: 4828036
    [No Abstract]   [Full Text] [Related]  

  • 40. [The venous occlusion test in assessing the fibrinolytic activity of the vascular endothelium in lupus nephritis patients].
    Bobkova IN; Poliantseva LR; Tareeva IE; Andreenko GV; Podorol'skaia LV
    Ter Arkh; 1995; 67(4):42-5. PubMed ID: 7784974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.